PDCD1 and sensory peripheral neuropathy: A recent meta-analysis of 3450 patients receiving PD-1/PD-L1 inhibitors demonstrated higher risk of all-grade rash, pruritus, hypothyroidism, hyperthyroidism, colitis, aminotransferase elevations, and pneumonitis but lower risk of all-grade AEs in general and lower risk of all-grade fatigue, sensory neuropathy, diarrhea, hematologic toxicities, anorexia, nausea, and constipation, and treatment discontinuation when compared to chemotherapy [72].